ESPEN 2012 - Late breaking abstract submission

Topic: Late Breaking Abstract

Abs n°:ESPEN12-1879

Abs Title: EFFECT OF INTRAVENOUS HIGH DOSE SELENIUM SUPPLEMENTATION IN PATIENTS WITH SYSTEMIC INFLAMMATORY RESPONSE SYNDROME: A PILOT STUDY

M. Kim ^1,*S. Kim ¹H. Baik ¹

¹Department of Internal Medicine, Bundang Jesaeng Hospital, SeongNam-Si, Korea, Republic Of

Rationale: There have been several reports published with conflicting results, which concerns the effect of high dose selenium supplementation to patients with systemic inflammatory response syndrome (SIRS). As such, we conducted a prospective, randomized, placebo-controlled trial to evaluate the effects of intravenous high dose selenium supplementation to patients with SIRS.

Methods: Patients were randomly assigned to one of the 2 groups: the selenium group, receiving 800 ㎍/day of selenoic acid by bolus intravenous injection for 7 days, or the placebo group. Physical and biochemical measurements were taken to check the following: serum selenium concentration, inflammatory markers, such as white blood cell (WBC) count and serum level of C - reactive protein (CRP), as well as, the severity of illness index, such as Acute Physiology and Chronic Health Evaluation II (APACHEII) score and Sequential Organ Failure Assessment (SOFA) score.

Results: A total of 23 patients were enrolled between March 2010 and October 2011. The serum selenium concentration increased in the selenium group after intervention, from 9.95 ㎍/㎗ to 15.15 ㎍/㎗, but there was no significant change in the control group from 10.70 ㎍/㎗ to 10.40 ㎍/㎗. In the selenium group, each of the WBC count, serum level of CRP, APACHEII score and SOFA score showed a significant improvement at day 7 and day 14, compared to day 0. In the control group, only the serum level of CRP of day 14 and APACHE II score of day 7 and 14 improved significantly, compared to day 0.

Conclusion: Intravenous supplementation of high dose selenium seems to improve the inflammatory markers and severity of illness index of patients with SIRS. However, larger prospective clinical trials are necessary to prove the efficacy of a selenium supplementation in SIRS patients.

Disclosure of Interest: None Declared

Keywords: SeleniumSystemic inflammatory response syndrome